腹外硬纤维瘤冷冻消融的临床与影像结局回顾研究
回顾分析2020—2024年接受影像引导冷冻消融的腹外硬纤维瘤患者,共44例中38例有随访资料,中位随访28.9个月。临床成功率为81.1%,1年、2年无进展生存率分别为76.5%和67.4%。研究表明冷冻消融对选择性腹外硬纤维瘤患者安全有效。
要点
- 影像引导冷冻消融可作为腹外硬纤维瘤多学科治疗选项之一
- 末次随访影像学反应以部分缓解最常见(54.1%),完全缓解24.3%
- 容积评估与mRECIST分类对疗效判断几乎完全一致(κ=0.895)
核心结论
- 冷冻消融对选择性腹外硬纤维瘤患者安全有效,多数患者获得临床成功
- 研究结果支持冷冻消融在硬纤维瘤多学科管理中的角色
研究设计与样本
- 回顾性研究,纳入2020—2024年经影像引导冷冻消融的腹外硬纤维瘤患者
- 208例硬纤维瘤患者中44例(20.7%)接受冷冻消融,38例有随访数据纳入分析
- 共实施92次冷冻消融,中位肿瘤大小6.9 cm(IQR 5.5-9.2),中位随访28.9个月(IQR 14.3-37.3)
关键影像表现/征象
- 末次随访时影像学表现为完全缓解24.3%,部分缓解54.1%,稳定16.2%,进展5.4%
诊断标准与关键数值
- 临床成功定义为末次随访无疾病进展、无需额外治疗且症状改善的复合终点,达成率81.1%
- 1年和2年无进展生存率分别为76.5%(95%CI 58.2-87.6%)和67.4%(95%CI 46.5-81.7%)
- 容积评估与mRECIST反应分类的观察者间一致性κ=0.895
- 主要不良事件(SIR分级≥3级)发生率为5.3%
临床应用与阅片要点
- 影像随访可采用容积评估或mRECIST分类判定疗效,两者几乎完全一致
- 26.3%患者因影像学进展需要重复冷冻消融,阅片时应关注进展征象
- 13.2%病例需要额外治疗方式,报告应提示疗效评估以辅助临床决策
局限性
- 回顾性研究设计,存在选择偏倚
- 单中心研究
- 纳入分析的患者中仅38例有完整随访数据,样本量有限
英文原文(摘要)· 点击展开
PURPOSE: To determine if image-guided cryoablation achieves durable clinical and radiologic response with an acceptable safety profile in patients with extra-abdominal desmoid tumors, and whether volumetric response assessment concords with mRECIST-based classification MATERIALS AND METHODS: Patients treated between 2020 and 2024 were identified through electronic record. Those who underwent cryoablation were included for analysis. The primary outcome was clinical success, defined as a composite of no disease progression at last follow-up, no additional treatment, and symptom improvement. Secondary outcomes included radiologic response, symptom improvement, progression-free survival (PFS), and safety. Among 208 patients diagnosed with desmoid tumors, 44 (20.7%) underwent cryoablation, and 38 had follow-up data available. 92 cryoablation sessions were performed. Median tumor size was 6.9 cm (IQR 5.5-9.2), and median follow-up duration was 28.9 months (IQR 14.3-37.3).
RESULTS: The clinical success rate was 81.1%. Radiologic response at last follow-up was complete in 24.3%, partial in 54.1%, stable in 16.2%, and progressive in 5.4%. Volumetric and mRECIST-based response classification showed almost-perfect agreement (κ = 0.895). Repeat cryoablation was performed in 26.3% of patients due to radiologic progression. Additional treatment modalities were required in 13.2% of cases. The 1- and 2-year PFS rates were 76.5% (95% CI: 58.2-87.6%) and 67.4% (95% CI: 46.5-81.7%), respectively. Major adverse events (SIR ≥3) occurred in 5.3% of patients.
CONCLUSION: Cryoablation is a safe and effective treatment option for selected patients with extra-abdominal desmoid tumors, achieving clinical success in the majority of patients. These findings support its role in the multidisciplinary management of desmoid tumors.
引用
- Journal of Vascular and Interventional Radiology:Cryoablation for Extra-Abdominal Desmoid Tumors: a Retrospective Study of Clinical and Radiological Outcomes
- Arseneault-Monette, Luo, Mack, et al. Cryoablation for Extra-Abdominal Desmoid Tumors: A Retrospective Study of Clinical and radiological outcomes. J Vasc Interv Radiol. 2026. PMID: 42731622. doi:10.1016/j.jvir.2026.109083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。